Garuda - Garba Rujukan Digital

Article Per Year (5 Year)

All

JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia

main
Website

Published by Badan Analisis dan Pengembangan Ilmiah Nasional ISMKI

ISSN : 23026391 EISSN : 27211924 DOI : https://doi.org/10.53366/jimki

Core Subject : Health,

Health Professions Medicine & Pharmacology Public Health

Jurnal Ilmiah Mahasiswa Kedokteran Indonesia (JIMKI) adalah jurnal yang dikelola oleh Badan Analisis dan Pengembangan Ilmiah Nasional (BAPIN). JIMKI berfokus menjadi wadah untuk publikasi penelitian mahasiswa kedokteran.

Arjuna Subject : Kedokteran - Kedokteran (Lain-Lain)

Articles 326 Documents

25 26 27 28 29

Comparative Efficacy and Safety of Limus-Eluting Stents in Acute Coronary Syndrome in Asian People: A Network Meta-Analysis and Bioinformatics Study Prazeva, Marista; Hendrawan, Adha; Habiby, Farhan
JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia Book of Abstrack RCIMS 2025
Publisher : BAPIN-ISMKI (Badan Analisis Pengembangan Ilmiah Nasional - Ikatan Senat Mahasiswa Kedokteran Indonesia)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.53366/jimki.vi.951

Introduction: Evidence on the relative performance of limus-eluting stents (LES) in acute coronary syndrome (ACS) among Asian patients is mixed, and formal rankings with biological context are limited. We compared LES and examined drug-specific mechanisms. Methods: Randomized trials of ACS patients undergoing PCI with 12-month outcomes were identified systematically. A frequentist network meta-analysis combined 19 trials (n=25,642) to estimate odds ratios (ORs) for major adverse cardiovascular events (MACE) and mortality and to derive treatment ranks (P-scores). Bioinformatics included molecular docking to FKBP12/mTOR/VEGFR2, ADMET/toxicity prediction, protein–protein interaction networks, and KEGG/GO enrichment. Results and Discussion: All limus stents lowered 12-month MACE versus paclitaxel (ZES 0.46 [0.34–0.64]; EES 0.55 [0.41–0.71]; SES 0.58 [0.46–0.72]; BES 0.60 [0.42–0.86]). Differences within the limus class were small (ZES vs SES 0.80 [0.62–1.06]). Rankings favored zotarolimus (SUCRA 0.94), followed by everolimus (0.64) and sirolimus (0.50); biolimus (0.42) ranked below, and paclitaxel was lowest. Mortality did not differ. Docking indicated stronger binding of limus agents to FKBP12/mTORC1 than paclitaxel, and toxicity models suggested a wider safety margin for limus agents (everolimus LD50 2,500 mg/kg; paclitaxel 134 mg/kg). Enrichment analyses highlighted PI3K–Akt/mTOR pathways relevant to vascular healing. Conclusion: In Asian ACS, LES outperform paclitaxel at 12 months. Zotarolimus ranks first, with everolimus and sirolimus performing comparably. The clinical ranking aligns with predicted target engagement and toxicity profiles.

Potential of Bioactive Peptides From Blanak Fish (Moolgarda Seheli) as Multitarget Therapy for Non-small Cell Lung Cancer: A Cancer-informatics Study Ramadhana, Reza; Maulana, Rafi; Al Habsy, Muhammab Nandito
JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia Book of Abstrack RCIMS 2025
Publisher : BAPIN-ISMKI (Badan Analisis Pengembangan Ilmiah Nasional - Ikatan Senat Mahasiswa Kedokteran Indonesia)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.53366/jimki.vi.952

Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer with a high mortality rate and resistance to conventional therapy. Moolgarda seheli is known to produce bioactive compounds, but its potential against NSCLC still needs to be explored. This study aims to evaluate the pharmacokinetic profile, pharmacodynamics, and potential of M. seheli peptides as a multitarget agent for NSCLC through an in silico approach. Twelve M.seheli peptides were modeled using UCSF Chimera. Pharmacokinetic and pharmacodynamic predictions were performed using SwissADME, ProTox-3.0, and AllerTop. Membrane permeability was evaluated using PerMM. Target protein structures were obtained from PDBJ. Molecular docking was performed with MOE, then validated through molecular dynamics simulation (MD) using YASARA. Plasmid construction was performed in silico using ApE v2.0.36. Pharmacokinetic and pharmacodynamic profiles indicate the AVMAPIVA peptide has favorable distribution, metabolism, and excretion, as well as non-toxic and non-allergenic properties. The AVMAPIVA peptide exhibits strong affinity for CDK4 (-10.75 kcal/mol), BRAF (-11.60 kcal/mol), AKT1 (-10.79 kcal/mol), VEGFR2 (-10.73 kcal/mol), and EGFR (-10.47 kcal/mol). PerMM results indicate good membrane penetration ability. MD simulations confirm the stability of the complex. The results of the study indicate that the AVMAPIVA peptide is non-toxic, non-allergenic, stable in biological environments, and capable of penetrating cell membranes and inhibiting proliferation, migration, and angiogenesis in NSCLC. peptide from M. seheli has potential as a multitarget therapy for NSCLC with a good druglikeness profile. In vitro and in vivo experimental studies are needed for further validation of efficacy and safety. Keywords: Moolgarda seheli, Multitarget, NSCLC, Peptide-based therapy, Bioinformatics.

Associations Between Genetic Variants and Adverse Effects of Gefitinib in Non-small Cell Lung Cancer: A Systematic Review Rangga Pradipa, Agya Marsaa; Al Ayyubi, Muhammad Shalahudin; Romadhona, Sabila
JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia Book of Abstrack RCIMS 2025
Publisher : BAPIN-ISMKI (Badan Analisis Pengembangan Ilmiah Nasional - Ikatan Senat Mahasiswa Kedokteran Indonesia)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.53366/jimki.vi.953

Introduction: Lung cancer remains the leading cause of cancer-related death worldwide, with non–small cell lung cancer (NSCLC) accounting for approximately 85% of cases. Gefitinib is a tyrosine kinase inhibitor frequently used in NSCLC with favorable outcome. However, many patients develop severe adverse effects which might be influenced by genetic variability. Therefore, we aim to systematically review the gene variants and its association with adverse effects of gefitinib in NSCLC patients. Methods: A systematic search was conducted according to PRISMA guidelines across PubMed, Scopus, and Cochrane. Studies investigating the association between genetic variations with adverse effects following gefitinib in NSCLC were included. Extracted data encompassed study and patient characteristics, adverse effects, and identified gene variations. Risk of bias was assessed using the RoB-2 for randomized trials and Newcastle–Ottawa Quality Assessment Scale for cohort and case–control studies. Results: Nineteen studies involving 2.087 patients were included, with Japanese populations being the most studied. Polymorphisms in EGFR and ABCG2 were among the most studied genes. Rash, diarrhea, and hepatotoxicity are the most common adverse effects reported. Poor metabolizers of CYP2D6 and CYP3A53/3, and variations in ABCG2, ABCB1, and EGFR were associated with higher incidence of adverse effects. However, several studies demonstrated no associations between gene variations with adverse effects. Conclusion: Genetic variations in ABCG2, ABCB1, CYP2D6, CYP3A53/3, and EGFR may influence gefitinib-associated adverse effects, highlighting the need of pharmacogenomic testing to guide personalized treatment and improved patient safety. Keywords: Pharmacogenomics, Genetic Variants, Gefitinib, Non-Small Cell Lung Cancer, Adverse Effects

Novel of Tuberculosis Vaccine Candidates through In Silico and In Vivo Analysis of Single Epitope Protein PE-PGRS Mycobacterium Tuberculosis Adha, Muhammad Alghifary; Maulana, Rafi; Mifindra, Rafhy
JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia Book of Abstrack RCIMS 2025
Publisher : BAPIN-ISMKI (Badan Analisis Pengembangan Ilmiah Nasional - Ikatan Senat Mahasiswa Kedokteran Indonesia)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.53366/jimki.vi.955

Tuberculosis (TB) is an infectious disease that remains a serious global health threat. The use of the Bacille Calmette–Guérin (BCG) TB vaccine has so far shown unsatisfactory results due to its inconsistent and limited effectiveness. In this study, a comprehensive preclinical study pipeline was developed to design a novel single-epitope subunit vaccine targeting the PE_PGRS protein family of Mycobacterium tuberculosis. VaxiJen screened antigenic proteins, IEDB and NetMHCpan predicted B- and T-cell epitopes. Selected epitopes were assembled with linkers and an adjuvant. The construct was expressed, purified, and tested in vivo in mice for antibody and cytokine responses. The construct result showed, which had a molecular weight of 35.1 kDa and an instability score of 16.58, was found to be stable, soluble, and somewhat hydrophilic by physicochemical examination. The three-dimensional model showed a tight and stable fold that was dominated by ?-sheets and ?-helices. Strong binding affinities with MHC class I (?G = ?22.7 kcal/mol) and class II (?G = ?10.9 kcal/mol) were confirmed by molecular docking and PRODIGY studies. In the in vivo test, the single epitope exposure group had an average value of 0.090 ± 0.017. This indicates that single epitope exposure provides a significant effective antigen presentation and T-cell activation and increase in the measured parameters compared to the control group. Collectively, these findings highlight the potential of the designed single-epitope construct as a safe, stable, and immunogenic vaccine candidate against M. tuberculosis, meriting further experimental validation.

Efficacy and Safety of Tyrosine Kinase 2 Inhibitor Deucravacitinib in Psoriasis : A Systematic Review and Drug-Response Meta Analysis of RCTs Putera, Rizky; Onggowasito, Livilia Abigail; Kynaya, Erlangga Masykur
JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia Book of Abstrack RCIMS 2025
Publisher : BAPIN-ISMKI (Badan Analisis Pengembangan Ilmiah Nasional - Ikatan Senat Mahasiswa Kedokteran Indonesia)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.53366/jimki.vi.961

Psoriasis is a chronic immune-mediated disease affecting 1–3% of the population worldwide and often impairs quality of life, with moderate-to-severe cases requiring systemic therapy. Deucravacitinib, a selective tyrosine kinase 2 (TYK2) inhibitor that modulates IL-23, IL-12, and type I interferon pathways, has emerged as a promising oral therapy. However, trial findings remain inconsistent, highlighting the need for systematic evaluation of its efficacy and safety versus placebo. A comprehensive literature search of PubMed, Scopus, Scilit, and ScienceDirect was performed to identify randomized controlled trials published up to 2025 comparing deucravacitinib with placebo in psoriasis. Risk of bias was assessed using the Cochrane RoB 2.0 tool, and meta-analysis was conducted with Rstudio with random effect model and REML estimator. Seven RCTs (n = 3,014) were included. Deucravacitinib significantly improved PASI-75 (OR = 9.85; 95% CI 5.11–19.01; p < 0.0001), PASI-90 (OR = 14.29; 95% CI 9.14–22.35; p < 0.0001), and PASI-100 (OR = 12.03; 95% CI 5.55–26.09; p < 0.0001), as well as sPGA 0/1 (OR = 14.28; 95% CI 9.30–23.62; p < 0.0001). Quality-of-life outcomes also improved: PSSD-0 (OR = 7.60; 95% CI 2.73–21.16; p = 0.0001) and DLQI 0/1 (OR = 6.27; 95% CI 4.68–8.41; p < 0.0001). Upper respiratory tract infection and acne were more frequent with deucravacitinib, while other adverse events were comparable to placebo. Meta-regression showed dose dependence for DLQI 0/1 (p = 0.02) and PSSD-0 (p = 0.01), but not for adverse events. Deucravacitinib demonstrates significant efficacy and acceptable safety in psoriasis treatment. Long-term studies are warranted to confirm its sustained safety profile. Keywords: Deucravacitinib, Psoriasis, TYK2 Inhibitor, Efficacy

Efektivitas Pemberian Polydeoxyribonucleotide (PDRN) dari Salmon Salar Melalui Microneedling vs Serum Topikal untuk Terapi Anti-Aging Hanifah, Asma Muthmainah; Fadhlillah, Jihan; Hanifah, Maryam
JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia Book of Abstrack RCIMS 2025
Publisher : BAPIN-ISMKI (Badan Analisis Pengembangan Ilmiah Nasional - Ikatan Senat Mahasiswa Kedokteran Indonesia)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.53366/jimki.vi.963

Penggunaan Polydeoxyribonucleotide (PDRN) marak diperbincangkan sebagai tren perawatan kulit anti-penuaan. Pada awalnya, perawatan wajah dengan bahan PDRN lebih umum dilakukan di klinik kecantikan menggunakan teknik microneedling. Namun, akhir-akhir ini industri kecantikan berusaha mengembangkan PDRN versi pelembab yang lebih mudah digunakan sehari-hari dan dikenal dengan pelembab yang memiliki kandungan DNA Salmon. PDRN diketahui berperan dalam aktivasi reseptor adenosine A2A yang dapat merangsang sintesis kolagen, mempercepat perbaikan jaringan, serta memberikan efek anti-inflamasi. Penelitian ini bertujuan untuk membandingkan efektivitas dan keamanan pemberian PDRN melalui teknik microneedling dan aplikasi topikal terhadap tanda-tanda penuaan kulit metode yang digunakan berupa tinjauan sistematis terhadap studi eksperimental dan klinis yang melaporkan efek kedua metode pada penyembuhan luka, perbaikan tekstur, elastisitas kulit, dan efek samping. Hasil analisis menunjukkan bahwa kedua metode sama-sama efektif meningkatkan kualitas kulit dengan efek samping minimal. Microneedling meningkatkan penetrasi intradermal, mempercepat regenerasi, serta mempercepat sintesis kolagen dan elastin, sedangkan aplikasi PDRN topikal memberikan efek sinergis dalam mengurangi stres oksidatif serta memperbaiki warna kulit, terkhusus bila dikombinasikan dengan penggunaan vitamin C atau niacinamide. Secara keseluruhan, kedua metode aman dan efektif untuk terapi anti-aging, tetapi metode microneedling menawarkan hasil regenerasi kolagen yang lebih cepat sementara aplikasi serum PDRN secara topikal menjadi alternatif non-invasif praktis. Pemilihan metode perawatan menggunakan PDRN lebih baik disesuaikan dengan preferensi, kondisi kulit, dan toleransi nyeri pasien terhadap prosedur.

Effectiveness of Bacillus Calmette–Guérin (BCG) Vaccine as Post-exposure Prophylaxis Against Leprosy Among Household Contacts: A Systematic Review Habiburrahman Al Ghifari; Yasmin Mazaya Bil Haqq; Atania Ilma
JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia Book of Abstrack RCIMS 2025
Publisher : BAPIN-ISMKI (Badan Analisis Pengembangan Ilmiah Nasional - Ikatan Senat Mahasiswa Kedokteran Indonesia)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.53366/jimki.vi.964

Introduction: Indonesia remains one of the top three countries with the highest leprosy burden. Current prevention focuses mainly on early detection. However, limited public awareness allows continued transmission, especially among household contacts (HHCs). Considering WHO’s 2030 “Toward Zero Leprosy” goal, post-exposure prophylaxis (PEP) with vaccines represents a promising strategy. Although no specific leprosy vaccine exists, Bacillus Calmette–Guérin (BCG) provides cross-protection due to antigenic similarity with Mycobacterium leprae. Its effectiveness is assessed through new leprosy cases and IgM anti-phenolic glycolipid-1 (PGL-1) antibody levels. Therefore, this systematic review aims to evaluate the effectiveness of BCG vaccination as post-exposure prophylaxis against leprosy among household contacts. Methods: Databases including PubMed, Springer, Nature, Frontier, Epistemonikos, ScienceDirect, BMJ, Sage, and Karger were searched. From 6,303 records, seven studies met inclusion criteria. Eligible studies were RCTs and cohort studies (2015–2025) on BCG-based PEP among household contacts. Non-English, in vitro, review, and non-field case reports were excluded. Study quality was assessed using JBI Critical Appraisal tools.Results and Discussion: Seven studies showed that BCG vaccination reduced leprosy incidence by 57–75%. The strongest protection occurred with BCG revaccination (59–95%), while combining BCG with single-dose rifampicin (SDR) achieved about 80% efficacy. Immunologically, vaccinated contacts showed lower IgM anti-PGL-1 levels, indicating a protective immune response. This indicates the vaccine’s ability to simulate a protective immune response that suppresses the humoral response against Mycobacterium leprae.Conclusion: BCG vaccination provides substantial protection as post-exposure prophylaxis against leprosy, while its revaccination or combination with SDR further strengthens preventive efficacy among household contacts.

Stem Cell-based Therapeutic Approaches For Thalassemia: A Systematic Review Rahayaan, Manuela; Hi Rauf, Siti Nuraini; Meralda, Arla Sindu
JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia Book of Abstrack RCIMS 2025
Publisher : BAPIN-ISMKI (Badan Analisis Pengembangan Ilmiah Nasional - Ikatan Senat Mahasiswa Kedokteran Indonesia)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.53366/jimki.vi.965

Thalassemia is a hereditary hematologic disorder characterized by defective hemoglobin synthesis, resulting in chronic anemia and rekated systemic complications, which are often managed through lifelong blood transfusions and iron chelation therapies. Recent advances in cell-based therapeutic strategies, particularly hematopoietic stem cell ( HCS ) gene therapy, have demonstrated substantial potential in addressing the underlying genetic defects and improving erythropoiesis. This systematic review evaluates preclinical and clinical studies, from PubMed, ScienceDirect, SCOPUS, focusing on the efficacy of HSC gene therapy and other immunomodulatory cellular approaches in thalassemia models. Studies involving thalassemic mice indicated that HCS-based gene therapy significantly enhanced ?-globin expression and restored normal red blood cell phenotypes, suggesting functional hematologic improvements. Complementary strategies involving regulatory T cells (Tregs) and engineered immune cells, including CAR-T and NK cells, offer additional promise for immune modulation, transplant tolerance, and the reduction of therapy-related complications. Despite these advances, challenges including limited cell availability, complex ex vivo culture conditions, immune rejection, and scalability remain. Innovations in genome editing, engineered TCR/CAR technology and CRISPR/Cas-edited iPSC-derived cells may further improve specificity, stability, and efficacy. Collectively, cell-based therapies offer a transformative approach for thalassemia by correcting the underlying genetic defect and modulating immune responses, with the potential to reduce dependence on conventional transfusions and enhance quality of life. Further clinical studies are required to establish long-term safety, feasibility and therapeutic efficiency in human patients

From Promise to Proof: Revealing the Comparative Performance of RSV Vaccines Through Network Meta-Analysis Madani, M. Iyad; Haq, Hilmi Amirul; Abdullah, Bryan Naufal
JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia Book of Abstrack RCIMS 2025
Publisher : BAPIN-ISMKI (Badan Analisis Pengembangan Ilmiah Nasional - Ikatan Senat Mahasiswa Kedokteran Indonesia)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.53366/jimki.vi.969

Introduction: There is no consensus on the optimal vaccine platform for preventing respiratory syncytial virus (RSV) infection. Recent advances in RSV vaccine development aim to improve efficacy and safety across various platforms. This study aimed to compare the efficacy and safety of available RSV vaccines using a network meta-analytic approach to identify the most effective strategy for RSV prevention.Method: A systematic search was performed in PubMed, ScienceDirect, Cochrane, and Scopus up to November 2025 to identify randomized controlled trials (RCTs) of RSV vaccines in healthy populations. Ten RCTs were included, evaluating adenovirus vaccine, subunit vaccine, mixed subunit and adenovirus vaccine, subunit vaccine with AS01E, and placebo controls were included. Analyses were conducted in RStudio using the netmeta package. Risk of bias was appraised using RoB 2.0 and certainty of evidence was assessed with CINeMA and the GRADE frameworks. Result and Discussion: This analysis demonstrated that the subunit vaccine with AS01E possesses superior efficacy in reducing RSV-related respiratory illness compared to placebo (RR = 0.22, 95% CI: 0.16 -- 0.31). This finding was reinforced by ranking analysis, which identified this intervention as the most effective (P-score = 0.916). No significant differences in safety profiles were observed across interventions, although precision was limited by wide confidence intervals and substantial heterogeneity. Conclusion: Subunit vaccines with AS01E demonstrated the highest efficacy for RSV prevention. However, their safety profile has not yet been clearly defined, and further research is needed to assess long-term effectiveness and monitor potential late adverse effects.

How Gut Microbiome Signatures Shape Metformin Response and GI Intolerance in Type 2 Diabetes Sari, Lia Nur Indah; Idrus, Citra Lorenza
JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia Book of Abstrack RCIMS 2025
Publisher : BAPIN-ISMKI (Badan Analisis Pengembangan Ilmiah Nasional - Ikatan Senat Mahasiswa Kedokteran Indonesia)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.53366/jimki.vi.973

Metformin is first-line therapy for type 2 diabetes mellitus (T2DM), yet interindividual variability in glycaemic response and frequent gastrointestinal (GI) intolerance are not fully explained by pharmacogenomics alone. This review synthesised evidence that links baseline gut microbiome composition to metformin effectiveness and tolerability. English-language, open-access Human observational studies from the past decade were identified in PubMed, ScienceDirect, and Google Scholar if they reported stool- or rectal sample–derived microbiome profiles alongside glycaemic outcomes (e.g., HbA1c change) or GI adverse events, dose modification, or discontinuation, with standardised extraction of design, population, -omics methods, and outcome definitions. Few eligible studies met criteria; across prospective and cross-sectional cohorts, higher alpha diversity and specific taxa—including Akkermansia and Streptococcus—were associated with increased GI adverse events to metformin, while distinct microbial signatures differentiated glycaemic responders from non-responders. A small multi-omic analysis suggested that shifts in bile acid–related bacteria together with down-regulation of anti-inflammatory host genes may underlie intolerance. Integrative models combining pharmacogenomic variants with microbiome features were rarely evaluated, and head-to-head comparisons with pharmacogenomics-only models are lacking. Overall, baseline gut microbiome signatures correlate with variability in metformin responses and GI intolerance in T2DM, underscoring the need for larger, standardised multi-omic cohorts to quantify the incremental predictive value of microbiome data for personalised metformin theraphy.

Page 27 of 33 | Total Record : 326

25 26 27 28 29

Filter by Year

2012 2026

Filter By Issues

Home Page

OAI Link

Editorial Team

Contact

Reviewer

Google Scholar

Contact Name
Norbertus Marcell Prayogi

Contact Email
editor.jimki.bapin@gmail.com

Phone
+6281372545321

Journal Mail Official
editor@jimki.bapin.or.id

Editorial Address
Jl. Dr. G.S.S.Y. Ratulangi No. 29, Menteng, Jakarta Pusat 10350

Location
Kota adm. jakarta pusat,

Dki jakarta

INDONESIA

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Home Page

OAI Link

Editorial Team

Contact

Reviewer

Google Scholar

Contact Name Norbertus Marcell Prayogi

Contact Email editor.jimki.bapin@gmail.com

Phone +6281372545321

Journal Mail Official editor@jimki.bapin.or.id

Editorial Address Jl. Dr. G.S.S.Y. Ratulangi No. 29, Menteng, Jakarta Pusat 10350

Location Kota adm. jakarta pusat, Dki jakarta INDONESIA

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Contact Name
Norbertus Marcell Prayogi

Contact Email
editor.jimki.bapin@gmail.com

Phone
+6281372545321

Journal Mail Official
editor@jimki.bapin.or.id

Editorial Address
Jl. Dr. G.S.S.Y. Ratulangi No. 29, Menteng, Jakarta Pusat 10350

Location
Kota adm. jakarta pusat,

Dki jakarta

INDONESIA